CLINICAL TRIALS PROFILE FOR IMURAN

All Clinical Trials for IMURAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001789 ↗	BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2	1999-06-01	The purpose of this study is to investigate whether the experimental drug BG9588 can be used to treat lupus nephritis more effectively and with less toxicity than standard treatments, including cyclophosphamide (Cytoxan), azothioprine (Imuran) and prednisone. The body's immune system naturally produces antibodies to fight foreign substances like bacteria and viruses. In autoimmune diseases like lupus, however, the body makes antibodies that attack its own tissues, causing inflammation and organ damage. Lupus antibodies attack and damage kidney cells. BG9588 can interfere with the production of these antibodies, and therefore, may lessen kidney damage in people with lupus nephritis. This study will look at: how BG9588 enters and leaves the blood and body tissue over time; adverse effects of the drug; and whether treatment with BG9588 can result in less kidney damage than other therapies. Study patients will be receive a 30-minute infusion of BG9588 into a vein every two weeks for three doses and then once every 28 days for four doses. Patients' steroid dosage may be tapered; individual adjustments will be made as required. Patients screened for the study will undergo a physical examination, medical history, various blood and urine tests, as well as complete a quality of life questionnaire. Results of a previous kidney biopsy and chest X ray are also required. Many of these tests will be repeated throughout the study. In a previous animal study, BG9588 treatment of mice with lupus nephritis improved their disease and survival.
NCT00098111 ↗	Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease	Terminated	Massachusetts General Hospital	Phase 3	2005-04-01	The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects.
NCT00104299 ↗	Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis	Completed	Genentech, Inc.	Phase 2/Phase 3	2005-01-01	Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 ↗	Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis	Completed	Immune Tolerance Network (ITN)	Phase 2/Phase 3	2005-01-01	Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 ↗	Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2/Phase 3	2005-01-01	Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00113503 ↗	Imuran Dosing in Crohn's Disease Study	Terminated	Prometheus Laboratories	Phase 2	2005-07-01	This study will compare two different dosing methods of azathioprine (IMURAN) in participants with Crohn's disease who are currently taking steroids (e.g. prednisone or budesonide)or who have just started steroids. The study can be up to 54 weeks long. All participants enrolled will receive active drug. Participants will take doses either based upon weight or based on the patient's ability to breakdown the drug (monitored by 6-thioguanine nucleotides (6-TGN) metabolite levels in the blood). All patients enrolled in the study will receive active study drug.

Clinical Trial Conditions for IMURAN

Condition Name

Condition Name for IMURAN
Intervention	Trials
Crohn's Disease	8
Lupus Nephritis	6
Ulcerative Colitis	3
Liver Diseases	2

Condition MeSH

Condition MeSH for IMURAN
Intervention	Trials
Crohn Disease	10
Nephritis	6
Lupus Nephritis	6
Vasculitis	3

Clinical Trial Locations for IMURAN

Trials by Country

Trials by Country for IMURAN
Location	Trials
United States	77
Canada	7
Netherlands	7
Italy	4
Japan	3

Trials by US State

Trials by US State for IMURAN
Location	Trials
New York	9
Ohio	8
Pennsylvania	6
Minnesota	6
California	5

Clinical Trial Progress for IMURAN

Clinical Trial Phase

Clinical Trial Phase for IMURAN
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	9
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for IMURAN
Clinical Trial Phase	Trials
Completed	18
Terminated	8
Unknown status	3

Clinical Trial Sponsors for IMURAN

Sponsor Name

Sponsor Name for IMURAN
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	3
University of Pennsylvania	2
Genentech, Inc.	2

Sponsor Type

Sponsor Type for IMURAN
Sponsor	Trials
Other	37
Industry	18
NIH	9

Imuran (Azathioprine) Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is Imuran and what is the drug’s clinical landscape?

Imuran is a brand of azathioprine, a thiopurine immunosuppressant used in transplant medicine and immune-mediated diseases. It is an established, older small-molecule therapy with a long history of clinical use, so “clinical trials updates” in this context largely reflect incremental studies, comparative regimens, safety/biomarker work, and ongoing post-marketing research rather than late-stage pivotal programs for new indications.

Which clinical trial activity is most relevant right now?

Azathioprine research has continued in the following clinical domains:

• Transplantation: regimen optimization (often in combination with corticosteroids and other immunosuppressants), and safety monitoring.
• Autoimmune disease: comparative effectiveness and dose/safety strategies in conditions such as inflammatory bowel disease and autoimmune hepatitis.
• Safety and pharmacogenomics: thiopurine metabolism and biomarker-driven risk reduction (e.g., TPMT and related metabolic pathways), plus monitoring of myelosuppression and hepatotoxicity.

Key practical implication for market and R&D planning: because azathioprine is off-patent in most jurisdictions, trials are typically not aimed at new molecular IP protection. They are aimed at label refinement, risk management, and clinical guideline alignment rather than generating a new exclusivity block.

What are the dominant safety and monitoring considerations driving real-world use and outcomes?

Across azathioprine programs and real-world adoption, the core clinical control points are consistent:

• Myelosuppression (neutropenia/leukopenia) and infection risk
• Hepatotoxicity
• Metabolic variability affecting thiopurine exposure
• Need for ongoing blood count and liver enzyme monitoring
• Genotype-guided or phenotype-guided risk mitigation (notably TPMT testing used in many settings)

From a commercial lens, these are the operational “purchase drivers” behind ongoing trial work because they determine prescriber confidence, adherence to protocols, and substitution behavior between thiopurines and alternatives.

---

How big is the azathioprine/imuran market and what segments matter most?

Imuran competes in the azathioprine therapeutic class with generic azathioprine in most major markets. Brand-specific share depends on:

• local generic availability and pricing
• hospital formularies and tender behavior
• clinical inertia and physician familiarity
• supply and reimbursement dynamics

For market sizing, azathioprine’s demand is best modeled by indication incidence and long-term treatment patterns:

1. Transplant immunosuppression (typically kidney and other solid organ use in combination regimens)
2. Inflammatory bowel disease (IBD) maintenance and steroid-sparing use
3. Autoimmune hepatitis and related autoimmune hepatopathies
4. Other immune-mediated indications where thiopurines remain in guideline pathways

Market structure

• Supply: generic azathioprine dominates most geographies; brand pricing must compete against low-cost generics.
• Demand: driven by chronic therapy needs, guideline-based steroid-sparing strategy, and long-term immunosuppression management.
• Switching pressure: increased use of other immunosuppressants and biologics shifts some demand at the margin, but azathioprine remains a lower-cost option and a mainstay when biologics are unsuitable or not accessible.

---

What is the competitive set and how does it shape pricing power for Imuran?

Imuran’s commercial profile is constrained by class-level substitution:

• Generic azathioprine: direct substitution and primary pressure on brand share.
• Alternative conventional immunosuppressants (e.g., methotrexate in specific disease patterns).
• Biologics and targeted small molecules in IBD and autoimmune liver disease: higher uptake in certain patient subsets but usually higher price and access constraints.

Commercial consequence

Imuran pricing power is limited to:

• settings where brand name is favored in protocols
• procurement contracts that lock in brand supply
• patient-physician preference and continuity of care
• supply assurance and tender outcomes

---

What are the key market drivers supporting continued azathioprine demand?

Even with generics and newer therapies, azathioprine demand persists due to:

• low cost relative to biologics
• long-standing clinician familiarity
• availability in multiple oral dosing forms
• role in steroid-sparing strategies
• continued guideline inclusion in certain indications and patient populations

Key friction factors

Demand can be constrained by:

• increased preference for newer agents in IBD where safety and monitoring burdens become decision points
• intolerance or contraindications in patients with metabolite risk profiles
• clinician hesitancy if TPMT or monitoring practices are not well embedded

---

What is the current projection for azathioprine / Imuran (volume and value) through the next 5 years?

Projection framework (brand-focused):

• Volume: stable to modestly declining, assuming continued substitution to generics and gradual shift to newer IBD/immunology agents.
• Value: flat to declining for branded Imuran as generics set the economic ceiling and tendering favors lowest-cost supply.
• Share: likely stable in brand-anchored formularies but pressured elsewhere.

Directional forecast

• Base case: modest volume softness; value declines due to generic pricing pressure.
• Downside case: faster migration to newer IBD therapies and tighter safety screening lowers azathioprine use in parts of the market.
• Upside case: sustained guideline positioning plus low switching costs and payer emphasis on cost-effective immunosuppression supports stable volumes.

---

How do clinical trial trends translate into commercial outcomes for Imuran?

Because azathioprine is mature, clinical studies mostly influence:

• prescribing confidence and protocol adoption (monitoring standards)
• patient selection (risk stratification with metabolism-related testing)
• guideline text updates that preserve or refine thiopurine placement in care pathways

Commercial translation

• Higher protocol adoption improves persistence (fewer discontinuations due to avoidable toxicity).
• Better risk stratification reduces early discontinuations and may stabilize utilization in competitive disease segments.

---

What is the practical R&D and lifecycle outlook for azathioprine brand strategy?

For a mature, off-patent molecule, lifecycle strategy typically shifts to:

• formulation improvements (if any remain)
• label and guideline optimization
• real-world evidence studies to support monitoring and risk reduction practices
• payer-focused economic dossiers emphasizing cost of therapy versus newer agents in appropriate subsets

For Imuran specifically, competitive differentiation rests less on mechanism and more on supply reliability, reimbursement position, and protocol presence.

---

Key Takeaways

• Imuran (azathioprine) is a mature, off-patent immunosuppressant where “clinical trial updates” largely reflect safety, risk stratification, and incremental regimen work rather than new IP-driven late-stage development.
• Market demand persists through chronic immune disease management, cost-effectiveness versus biologics, and ongoing steroid-sparing use.
• Brand value is structurally pressured by generic azathioprine pricing; the more competitive the tendering environment, the less pricing power Imuran has.
• 5-year outlook is stable-to-modestly declining volumes and flat-to-declining value for the brand, with variability driven by IBD treatment migration and local payer/formulary behavior.
• Studies that improve TPMT-aware risk management and monitoring compliance can support persistence and reduce early discontinuations, stabilizing utilization in the face of newer therapies.

---

FAQs

1) Is Imuran still being studied in clinical trials?

Yes, but activity is typically focused on optimizing safety, monitoring, patient selection, and regimen use in established indications rather than new late-stage pivotal trials.

2) What determines whether a patient stays on azathioprine long term?

Blood count and liver monitoring discipline, dose management, infection surveillance, and risk stratification based on thiopurine metabolism variability.

3) What is Imuran’s biggest commercial headwind?

Generic azathioprine pricing and broad substitution in most markets.

4) Where does azathioprine still hold market relevance against newer therapies?

In cost-sensitive settings and patient subsets where steroid-sparing immunosuppression is needed and biologics or targeted agents are not appropriate or accessible.

5) What evidence is most likely to change practice for azathioprine?

Data that improves toxicity prediction, reduces discontinuation rates, and aligns with guideline updates on monitoring and safe dosing.

---

References

[1] FDA. Drug Safety Information.
[2] EMA. Azathioprine product information and safety updates.
[3] Clinical guideline publications for IBD and autoimmune hepatitis (thiopurines monitoring and TPMT testing recommendations).
[4] PubMed-indexed reviews on azathioprine pharmacogenomics and thiopurine safety monitoring (TPMT-related risk stratification).